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INTRODUCTION 
SAM-e is a nutrient supplement used for the relief of 
depression. Osteoarthritis, liver cirrhosis mainly reverses 
the alcoholic side effects.it was first described in 1952 and 
has been available in the United States as an over the 
counter supplementsince 1999; in Europe, it is a 
prescription medicine1 ,since 1975, where it is used to treat 
arthritis and depression.2 
 
it was first developed as a pharmaceutical by an Italian 
firm in the early 1970s. To date, it remains one of the most 
widely prescribed antidepressants in Italy.3it must be 
remembered that SAMe is not considered a drug in the 
United States and is therefore not subject to 
federalregulations. (In contrast, Samyr is a prescription 
drug in Italy and is available in 200 mg and 400 mg 
doses.)the iupac name is[(3S)-3-amino-3-
carboxypropyl]({[(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-
yl)-3,4-dihydroxyoxolan-2-yl]methyl})methylsulfanium . 
Recent testing by ConsumerLab.com of over-the-counter 
brands of SAMe in the United States found, on average, 
that for 6 of the 13 brands tested, less than half the amount 
of SAMe stated on the label was actually present. 
ROLE OF SAM-e IN OUR BODY 
SAM-e is found in almost every tissue in the body in 
humans and other mammals, formed by an enzyme 
(methionine S-adenosyltransferase (MAT)) catalyzed 
reaction between methionine and ATP (Osman et al., 
1993; LEF Magazine, 1997) and Methionine 
adenosyltransferase (MAT) which  is an essential cellular 
enzyme that catalyzes the formation ofS-
adenosylmethionine (SAM-e), the principal biological 
methyl donor and the ultimate source of the propyl 
aminemoiety used in polyamine biosynthesis.4 It also plays 
a role  in cellular metabolism as a methyl donor for 
transmethylation reactions and also acts as the amino 
propyl donor in the biosynthesis of polyamines[ 5,6]. 
GENERAL MECHANISM OF ACTION 
SAM-e is a ubiquitous methyl-donor molecule located 
throughout the body. It plays a keyrole in numerous 
metabolic pathways that involve the transfer of methyl 
groups. SAMeis not sufficiently available in our diet , but 
it  is formed in the body by thecombination of adenosine 
triphosphate (ATP) and the amino-acid methionineSAM-e 
then donates its methyl group to any of a wide range of 
molecules andis subsequently transformed to 
homocysteine.7 
it is mainly involved in SAM CYCLE (The reactions that 
produce, consume, and regenerate SAM are called the 
SAM cycle). In the first step of this cycle, the SAM-
dependent methylase that use SAM as a substrate produce 
s-adenosylhomocysteine as a product. This is hydrolysed 
to homocysteine and adenosine by S-
adenosylhomocysteine hydrolase and the homocysteine 
recycled back to methionine   through transfer of a methyl 
group from 5-methyltetrahydrofolate , by one of the two 
classes of methionine synthases This methionine can then 
be converted back to SAM, completing the cycle. 
PHARMACOLOGY 
Oral SAMe has a very low bioavailability, estimated to be 
< 1%, so its usefulness as anoral agent is open to question.8  
few recent studies reveals that 71% of the patients 
treatedwith oral SAM-e had a rise in their serum SAM-e 
concentrations9Parenterallyadministered SAM-e does 
appear to cross the blood brain barrier.10The half-
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life,metabolism, and excretion of SAM-e have not been 
well defined and much more studies are to be done to 
confirm it. 
Role of SAMe in treating depression 
SAMe has been shown to decrease depression,11. It has 
been hypothesized that the antidepressant effects of SAM-
e may result from its role as a methyl donor to biogenic 
amines which influence neurotransmitter metabolism, and 
from its role in the methylation of membrane 
phospholipids which modify membrane fluidity and 
receptor function (Bottiglieri& Hyland, 1994; Cestaro, 
1994; Cowley & Underwood, 1999). 
The antidepressant effects of SAMe were first suggested 
by Pinzello and Andreoli (1972). Since then, researchers 
have published some 40 open and double-blinded studies 
evaluating the efficacy of SAMe supplements for the 
treatment of depressive disorders in roughly 1,400 
subjects. Several studies have shown that SAMe can 
produce clinical improvement in depressed subjects as 
effectively as classic tricyclic antidepressants. SAMe also 
demonstrated antidepressant activity in several predictive 
models 
in mice and rats (Baldessarini, 1987; De Leo, 1987; 
Kaganet al., 1990; Rosenbaum et al., 1990; Czyraket al., 
1992; Bressa, 1994; Benelliet al., 1999; Cowley and 
Underwood, 1999). 
SAMe has not been more effective than prescription 
antidepressants, but it is clearly less toxic than the 
tricyclics and MAO inhibitors. Until large clinical trials 
confirm the results seen from the limited European studies, 
however, it is unlikely that American doctors will 
recommend SAM-e to severely depressed persons (Cowley 
& Underwood, 1999). 
Role in reversing liver injury caused due to alcohol. 
Many studies indicated that SAM-e has reversed the 
alcoholic injury, and it can be successfully to boost 
liver.Hepatic SAM levels are decreased in animal models 
of alcohol liver injury and in patients with alcohol liver 
disease or viral cirrhosis by acting against alcohol and 
cytochrome P450 2E1- dependent cytotoxicity both in 
vitro and in vivo . SAM-e, at high concentrations, inhibits 
CYP2E1 catalytic activity, lowering formation of ROS12. 
Animal studies and clinical trials in humans have shown 
that SAMe, administered orally or by injection, alleviates 
signs and/or symptoms of liver disease caused by alcohol 
(humans, rats, and baboons) (Micaliet al., 1983; Feoet al., 
1986; Lieberet al., 1990); toxic chemicals, including 
carbon tetrachloride (rats) (Varela-Moreiraset al., 1995) 
and hexachlorobenzene (rats) (Cantoniet al., 1990); 
nonsteroidal anti-inflammatory drugs (NSAIDs), including 
acetaminophen (mice) (Bray et al., 1992); and cyclosporin 
A (rats) (Galánet al., 1999). SAMe also alleviated 
estrogen-induced liver problems (e.g., cholestasis 
associated with pregnancy) (Almasioet al., 1990; 
Frezza&Terpin, 1992; Osman et al., 1993; Floreaniet al., 
1996) and hepatic necrosis in rats from methyl deficient 
diets (Chawlaet al., 1998). 
Role in Alzemer disease. 
Alzheimer disease, is the most common form of dementia. 
There is no cure for the disease, which worsens as it 
progresses, and eventually leads to death the cause and 
progression of Alzheimer's disease are not well 
understood. Research indicates that the disease is 
associated with plaques and tangles in the brain. Current 
treatments only help with the symptoms of the disease. But 
SAM-e shows its role effectively in reducing the cause of 
it as the antibody accumulation is one of the reason 
foAlzheimer’s to occur so it works by reducing the 
antibody accumulation 
Mechanism of action 
balance of presenilin activity or of their expression could 
be primarily responsible for Ab accumulation. The 
progressive SAM reduction observed in the elderly and the 
consequent methylation decrease, possibility of 
therapeutically reducing Ab production. It is unclear 
whether Ab accumulation is due to its overproduction or to 
a clearance defect. However, the reduction of Ab 
formation has a good chance of preventing AD. 13 
Osteoarthritis  
SAM-e has a comparable effect to that of NSAIDs in 
reducing pain and functional limitation.14Researchers 
discovered the potential usefulness of SAM-e for treating 
osteoarthritis by accident. They were studying SAM-e’s 
effect on depression when the patients they were following 
reported an unexpected improvement in their osteoarthritis 
symptom. SAMe is critical for manufacturing joint 
cartilage and for maintaining neural cell membrane 
function (Vibrant Life, 1999). People who suffered from 
osteoarthritis, rheumatoid arthritis, yfibromylagia, joint 
injuries, and osteoporosis have been treated successfully 
with SAM-e (Glorioso et al., 1985; Marcolongo et al., 
1985; DiPadova, 1987; König, 1987; Maccagno et al., 
1987; Vetter, 1987). A dozen European clinical trials 
involving more than 22,000 patients have found SAM-e to 
be effective for treatment of joint pain and inflammation 
from arthritis.Side effects include occasional 
gastrointestinal disturbances, mainly diarrhea6. in 
methylation reactions that aid in the production of cartilage 
proteoglycans.13A number of studies have found SAMe to 
be more effective than placebo in improving pain and 
stiffness related to osteoarthritis.15-19No studies 
documenting disease arrest or reversal are found in the 
literature20.  But it is found that it can treat for some extent. 
CONCLUSION 
SAMe though it is a super nutrient it should be taken with 
an prescription only as most of the effects it caused is 
unknown till now, and many more studies are need to be 
done on this, especially its studies should be conducted on 
liver regeneration effect of it, and has it shows promising 
effects on treating depression studies should be done to 
make it as a perfect drug. 
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